Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on July 12, 2004

Circulation. 2004
Published online before print July 12, 2004, doi: 10.1161/01.CIR.0000136580.34604.B8
A more recent version of this article appeared on July 27, 2004
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
110/4/374    most recent
01.CIR.0000136580.34604.B8v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sawhney, N.
Right arrow Articles by Teirstein, P. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sawhney, N.
Right arrow Articles by Teirstein, P. S.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ACETYLSALICYLIC ACID
Medline Plus Health Information
*Angioplasty
Related Collections
Right arrow Angioplasty and Stenting
Right arrow Restenosis
Right arrow Catheter-based coronary interventions: stents

Submitted on February 6, 2004
Revised on May 6, 2004
Accepted on May 10, 2004

Treatment of Left Anterior Descending Coronary Artery Disease With Sirolimus-Eluting Stents

Neil Sawhney MD, Jeffrey W. Moses MD, Martin B. Leon MD, Richard E. Kuntz MD, Jeffrey J. Popma MD, William Bachinsky MD, Theodore Bass MD, Samuel DeMaio MD, Edward Fry MD, David R. Holmes Jr MD, and Paul S. Teirstein MD*

From the Division of Cardiology, Scripps Clinic, San Diego, Calif (N.S., P.S.T.); the Cardiovascular Research Foundation, New York, NY (J.W.M., M.B.L.); Harvard Clinical Research Institute, Boston, Mass (R.E.K.); Brigham and Women’s, Boston, Mass (J.J.P.); Harrisburg Hospital, Harrisburg, Pa (W.B.); the University of Florida, Jacksonville (T.B.); Seton Medical Center, Austin, Tex (S.D.); St Vincent’s Hospital, Indianapolis, Ind (E.F.); and the Mayo Clinic, Rochester, Minn (D.R.H.).

* To whom correspondence should be addressed. E-mail: pteirstein{at}scrippsclinic.com.

Background--Revascularization strategies often hinge on the presence and degree of left anterior descending coronary artery (LAD) stenosis. A decision for bypass surgery is often based on the durability of surgical LAD revascularization compared with percutaneous approaches. By decreasing restenosis, drug-eluting stents may have reduced the "reintervention gap" between surgery and percutaneous intervention, making the percutaneous route preferable.

Methods and Results--Of the 1101 patients in the SIRIUS trial, 459 with an LAD stenosis were randomized to percutaneous intervention with either sirolimus-eluting or bare-metal stents. Baseline demographic, clinical, and angiographic data were obtained. Patients had 1-year clinical and 8-month angiographic follow-up. Baseline characteristics were similar in both groups. The majority of lesions were tubular type B lesions (69.7%) with a mean diameter of 2.73 mm and a mean length of 14.0 mm. The binary in-stent restenosis rate was 2% for the sirolimus stent group and 41.6% for the bare-metal arm (relative risk, 0.05; 95% CI, 0.02 to 0.1; P<0.001). One-year major adverse events (defined as cardiac death, Q-wave and non-Q-wave myocardial infarction, or target vessel revascularization) was decreased 59% in the sirolimus-stent group (9.8% versus 24.9%; relative risk, 0.39; 95% CI, 0.26 to 0.61; P<0.001). Subgroup analysis of 135 patients with proximal LAD lesions showed similar benefits. In-stent restenosis was 0 in the proximal LAD sirolimus-eluting group (n=67), compared with 38% in the bare-metal arm (n=68), and major adverse events demonstrated a similar trend, with a 50% decrease compared with control patients (10.4% versus 20.6%, P=NS).

Conclusions--Sirolimus-eluting stents significantly decrease revascularization rates in LAD lesions. At 1 year, sirolimus-eluting stent revascularization rates are comparable to historic single vessel bypass surgery revascularization rates.


Key words: angioplasty • stents • cardiovascular disease




This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
Y. Ben-Gal, R. Mohr, R. Braunstein, A. Finkelstein, N. Hansson, A. Hendler, Y. Moshkovitz, and G. Uretzky
Revascularization of Left Anterior Descending Artery With Drug-Eluting Stents: Comparison With Minimally Invasive Direct Coronary Artery Bypass Surgery
Ann. Thorac. Surg., December 1, 2006; 82(6): 2067 - 2071.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
H. B. Barner
Status of percutaneous coronary intervention and coronary artery bypass.
Eur. J. Cardiothorac. Surg., September 1, 2006; 30(3): 419 - 424.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
I. Herz, Y. Moshkovitz, D. Loberman, G. Uretzky, R. Braunstein, A. Hendler, E. Zivi, Y. Ben-Gal, and R. Mohr
Drug-Eluting Stents Versus Bilateral Internal Thoracic Grafting for Multivessel Coronary Disease
Ann. Thorac. Surg., December 1, 2005; 80(6): 2086 - 2090.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. Thiele, S. Oettel, S. Jacobs, R. Hambrecht, P. Sick, J. F. Gummert, F. W. Mohr, G. Schuler, and V. Falk
Comparison of Bare-Metal Stenting With Minimally Invasive Bypass Surgery for Stenosis of the Left Anterior Descending Coronary Artery: A 5-Year Follow-Up
Circulation, November 29, 2005; 112(22): 3445 - 3450.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. S. Douglas Jr, D. R. Holmes Jr, D. J. Kereiakes, C. L. Grines, E. Block, Z. M.B. Ghazzal, D. C. Morris, H. Liberman, K. Parker, C. Jurkovitz, et al.
Coronary Stent Restenosis in Patients Treated With Cilostazol
Circulation, November 1, 2005; 112(18): 2826 - 2832.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
Y. Moshkovitz, R. Mohr, R. Braunstein, E. Zivi, G. Uretzky, Y. Ben-Gal, and I. Herz
Revascularization of Left Anterior Descending Coronary Artery in Patients With Single and Multivessel Disease: Comparison Between Off-Pump Internal Thoracic Artery and Drug-Eluting Stent
Chest, August 1, 2005; 128(2): 804 - 809.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. Tsagalou, A. Chieffo, I. Iakovou, L. Ge, G. M. Sangiorgi, N. Corvaja, F. Airoldi, M. Montorfano, I. Michev, and A. Colombo
Multiple Overlapping Drug-Eluting Stents to Treat Diffuse Disease of the Left Anterior Descending Coronary Artery
J. Am. Coll. Cardiol., May 17, 2005; 45(10): 1570 - 1573.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. J. Drenth, F. Zijlstra, P. W. Boonstra, N. Sawhney, P. S. Teirstein, J. W. Moses, M. B. Leon, R. E. Kuntz, J. J. Popma, W. Bachinsky, et al.
Letter Regarding Article by Sawhney et al, "Treatment of Left Anterior Descending Coronary Artery Disease With Sirolimus-Eluting Stents" * Response
Circulation, April 26, 2005; 111(16): e265 - e266.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. J. Kereiakes, R. E. Kuntz, L. Mauri, and M. W. Krucoff
Surrogates, substudies, and real clinical end points in trials of drug-eluting stents
J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1206 - 1212.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
W. W. O'Neill, S. R. Dixon, and C. L. Grines
The year in interventional cardiology
J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1117 - 1134.
[Full Text] [PDF]


Home page
Eur Heart JHome page
Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al.
Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology
Eur. Heart J., April 2, 2005; 26(8): 804 - 847.
[Full Text] [PDF]